CompaniesKarus Therapeutics

Karus Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (3)
View all

Total Trials

3

As Lead Sponsor

3

As Collaborator

0

Total Enrollment

43

By Phase

PHASE2: 1PHASE1: 2

By Status

COMPLETED: 2WITHDRAWN: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Today
NCT02679196
NCT03008018
NCT04186156
Hover over trial bars to see details

Recent Trials

NCT04186156Lead Sponsor
A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer
PHASE2Withdrawn
Started: Mar 5, 2020 · Completed: Oct 31, 2023
NCT03008018Lead Sponsor
Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours
PHASE1Completed
20 participants
Started: Aug 7, 2017 · Completed: Jun 10, 2020
NCT02679196Lead Sponsor
The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma
PHASE1Completed
23 participants
Started: Jul 31, 2016 · Completed: Dec 24, 2018